Citation Impact
Citing Papers
Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
2011
Probing the Probes: Fitness Factors For Small Molecule Tools
2010
Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not
2012
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
2015
The molecular hallmarks of epigenetic control
2016 Standout
Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review
2020 Standout
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
2016 Standout
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
2011
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
2011 Standout
Strategies to Inhibit Myc and Their Clinical Applicability
2017
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Targeting apoptosis in cancer therapy
2020 Standout
Epigenetic protein families: a new frontier for drug discovery
2012
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
2013
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
2014
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer
2013 StandoutNobel
Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
2013 Standout
Tumour-microenvironmental interactions: paths to progression and targets for treatment
2010
Emerging targeted agents in metastatic breast cancer
2013
Modeling neurodevelopmental disorder-associated humanAGO1mutations inCaenorhabditis elegansArgonautealg-1
2024 StandoutNobel
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
2022
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis
2020
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
2015
Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency
2010
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
2011 Standout
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
Analysis of nanoparticle delivery to tumours
2016 Standout
Modeling and Targeting MYC Genes in Childhood Brain Tumors
2017
The Essential Medicinal Chemistry of Curcumin
2017 Standout
Works of Steven DellaRocca being referenced
Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
2012
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2016
CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
2010
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer
2009
CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
2009
The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL
2016
Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma
2018